IMRX Immuneering Corporation
$3.83▲ +3.23%
Healthcare
Other
After hours
$3.83▲ +0.00%
Oct 27, 4:01 PM ET
Volume 699.5K
Avg Volume (10D) 688.9K
Key Metrics & Fundamentals
Market Cap
$247.79M
P/E Ratio
–
Div Yield
0.00%
52W Range
3.38 - 8.48
% vs 50 MA
-12.15%
% vs 200 MA
-20.44%
RSI-14
45.6
MACD Histogram
+0.0400
Beta (1Y vs SPY)
1.04
Free Cash Flow
-$16.53M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$18.91M
COGS
–
Operating Exp
$19.00M
Operating Income
-$19.00M
EBIT
-$19.00M
Pretax Income
-$17.27M
Net Income
-$17.27M
EPS (Diluted)
-0.27
Price & Volume History
Loading chart…
Recent News
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
GlobeNewswire · Oct 26, 2026 7:30 AM ET
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
GlobeNewswire · Oct 2, 2026 9:00 AM ET
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
GlobeNewswire · Sep 28, 2026 7:30 AM ET
Immuneering to Present at the ESMO Congress 2026
GlobeNewswire · Sep 24, 2026 7:30 AM ET
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
GlobeNewswire · Sep 10, 2026 7:30 AM ET
Immuneering to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 3, 2026 4:05 PM ET
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
GlobeNewswire · Aug 26, 2026 5:16 PM ET
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
The Fly · Aug 6, 2026 9:48 AM ET
HC Wainwright Initiates Immuneering at Buy With $14 Price Target
MT Newswires · Aug 6, 2026 7:18 AM ET
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire · Aug 5, 2026 7:30 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See IMRX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.